Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with prostate cancer and indicated for androgen deprivation therapy (ADT)
Decision made to prescribe ADT prior to enrolment
Willing and able to provide written informed consent
You may not be if
Participation in an interventional clinical study in which any treatment or follow-up is mandated
Treatment with a GnRH receptor antagonist other than FIRMAGON
Had previous or is currently under hormonal management of prostate cancer, except for subjects who have undergone therapy with curative intention where neoadjuvant/adjuvant therapy allowed for maximum 6 months. Treatment should be terminated at least 6 months prior to baseline.
